IRIS
CRIMI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.536
AS - Asia 2.976
EU - Europa 987
SA - Sud America 414
AF - Africa 235
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.480
CN - Cina 1.259
SG - Singapore 1.125
IT - Italia 472
KR - Corea 404
BR - Brasile 366
IE - Irlanda 233
CI - Costa d'Avorio 161
IN - India 52
RU - Federazione Russa 44
GB - Regno Unito 42
SN - Senegal 42
CA - Canada 34
FI - Finlandia 33
VN - Vietnam 32
DE - Germania 26
NL - Olanda 25
UA - Ucraina 24
AR - Argentina 19
SE - Svezia 17
IQ - Iraq 15
PL - Polonia 15
JP - Giappone 14
MX - Messico 14
FR - Francia 13
NG - Nigeria 12
AT - Austria 11
TR - Turchia 11
ZA - Sudafrica 11
BD - Bangladesh 10
CO - Colombia 10
ES - Italia 8
PK - Pakistan 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
EC - Ecuador 5
HK - Hong Kong 5
MA - Marocco 4
NP - Nepal 4
SA - Arabia Saudita 4
BE - Belgio 3
ID - Indonesia 3
JO - Giordania 3
LT - Lituania 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
AU - Australia 2
AZ - Azerbaigian 2
CL - Cile 2
DK - Danimarca 2
EU - Europa 2
GR - Grecia 2
IR - Iran 2
KG - Kirghizistan 2
KZ - Kazakistan 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CG - Congo 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
MC - Monaco 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
TN - Tunisia 1
Totale 8.153
Salva come PNG Salva come JPEG
Città #
Dallas 1.283
Hefei 782
Santa Clara 762
Singapore 731
Seoul 404
Dublin 233
Chicago 191
Boardman 177
Abidjan 161
Ashburn 113
Beijing 107
Chandler 100
Los Angeles 77
Catania 74
Civitanova Marche 66
Dakar 42
Milan 41
Palermo 39
São Paulo 38
Jacksonville 34
Lappeenranta 27
Pune 23
Seattle 20
Lawrence 19
Rome 19
Andover 18
Cambridge 18
Council Bluffs 18
Toronto 17
Brooklyn 15
Des Moines 14
New York 14
Nanjing 13
Rio de Janeiro 13
Abuja 12
Warsaw 12
Kochi 11
Tokyo 11
Naples 10
Phoenix 10
San Francisco 10
Amsterdam 9
Bremen 9
Dong Ket 9
Giarre 9
Johannesburg 9
Salvador 9
Atlanta 8
Reggio Emilia 8
Wilmington 8
Belo Horizonte 7
Brasília 7
Campinas 7
Chennai 7
Manchester 7
Montreal 7
Munich 7
Shenyang 7
Assago 6
Corbetta 6
Gravina di Catania 6
Ho Chi Minh City 6
Stockholm 6
Abbiategrasso 5
Amiens 5
Bologna 5
Helsinki 5
London 5
Mexico City 5
Mumbai 5
Nanchang 5
Praia Grande 5
Secaucus 5
Charlotte 4
Dhaka 4
Fortaleza 4
Grafing 4
Hanoi 4
Madrid 4
Mascali 4
Paris 4
Pisa 4
Porto Alegre 4
Ribeirão Preto 4
Rimini 4
São José dos Campos 4
Ankara 3
Baghdad 3
Bogotá 3
Boston 3
Brussels 3
Carapicuíba 3
Cesa 3
Columbus 3
Curitiba 3
Dordrecht 3
Gravina in Puglia 3
Hamilton 3
Hebei 3
Hong Kong 3
Totale 6.087
Salva come PNG Salva come JPEG
Nome #
Practice of oxygenation and respiratory support during fibreoptic bronchoscopy: the OxyFOB study protocol 367
Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer 97
Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction 94
Bronchodilator response as a marker of poor asthma control 92
Rugarli. Medicina interna sistematica 89
Protective effect of Resveratrol on TGF-beta-induced lung fibroblast differentiation 88
Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients 86
State of the art in interstitial pneumonia with autoimmune features: A systematic review on retrospective studies and suggestions for further advances 85
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study 81
Acute and long-term management of severe bronchiectasis with high flow nasal therapy: A case report 79
Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics 79
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study 78
Exhaled breath condensate cysteinyl leukotrienes (cys-LTs) in gastroesophageal reflux disease-related asthma 77
Reliability and usefulness of a rapid IgM‐IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report 77
Mutual Interaction Between Human Lung Fibroblasts And T LymphocyteS 75
Use of ketamine in patients with refractory severe asthma exacerbations: systematic review of prospective studies 74
Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study 73
Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells 73
Prevalence and determinants of co-morbidities in patients with obstructive apnea and chronic obstructive pulmonary disease 73
Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study 72
High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial 72
Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study 70
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps 68
Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy 67
Diastolic Function and Positive Airway Pressure: More Research Is Warranted 66
Point-of-care blood eosinophil count in a severe asthma clinic setting 66
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma 64
Intermittent abdominal pressure ventilation management in neuromuscular diseases: a Delphi panel Consensus 64
Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study 64
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study 63
Prolonged respiratory failure: when doctor and family connect, the patient wins 62
Continuous vs intermittent Non-Invasive blood pressure MONitoring in preventing postoperative organ failure (niMON): study protocol for an open-label, multicenter randomized trial 62
Anti-inflammatory role of vitamin D in muscle dysfunctions of patients with chronic obstructive pulmonary disease: a comprehensive review 61
Is the Power Spectrum of Electromyography Signal a Feasible Tool to Estimate Muscle Fiber Composition in Patients with COPD? 61
Diagnostic delay in bronchiectasis: an Italian perspective 60
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy 58
Adherence to omalizumab: A multicenter "real-world" study 58
A European survey of Non- Invasive Ventilation (NIV) 57
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis 57
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression 57
Bronchial reversibility testing: an index of poorly controlled asthma 57
Exhaled breath condensate pH and cysteinyl leukotriens in patients with chronic cough secondary to acid gastroesophageal reflux 57
Personalized Medicine in Asthma: Current Approach and Future Perspectives 56
Asthma severity: the patient’s point of view 56
Tezepelumab for asthma 56
The accuracy of the HemoCue WBC DIFF in assessing blood eosinophils depends on the clinical setting and medical condition 56
Impact of chronic obstructive pulmonary disease on passive viscoelastic components of the musculoarticular system 56
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study 55
Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections 55
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab 54
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission 53
Misdiagnosis of asthma and COPD and underuse of spirometry in primary care unselected patients 52
A Key to Unlocking the Mysteries of COVID-19 Pulmonary Sequelae: Are We There? 52
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis 52
Performance of EasyBreath Decathlon Snorkeling mask for delivering continuous positive airway pressure 52
Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program 52
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma 52
Impact of asthma on bronchiectasis severity and risk of exacerbations 52
Challenges for the female health-care workers during the COVID-19 pandemic: the need for protection beyond the mask 51
Eosinophilic Bronchiectasis: Prevalence, Severity, and Associated Features—A Cohort Study 51
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience 51
Effects of high-flow nasal therapy on swallowing function: a scoping review 50
Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI) 50
Domiciliary Non-invasive Ventilation in COPD: An International Survey of Indications and Practices 50
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study 50
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13 50
Fully covered self-expandable metal stent (SEMS) in tracheo-bronchial disorders: clinical experience 49
Effect of high-flow nasal therapy on dyspnea, comfort, and respiratory rate 49
REINVENT: ERS International survey on REstrictive thoracic diseases IN long term home noninvasive VENTilation 49
Are we overlooking the lung function in the definition of severe asthma remission? 49
Airway hyperresponsiveness with chest strapping: effects of heterogeneity and reduced lung volume 49
Ultrasound-guided placement of long peripheral cannula in children with cystic fibrosis 49
Long-term home noninvasive ventilation (LTHNIV) in restrictive thoracic diseases: The Italian snapshot 49
Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma 49
Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis 49
Biologics in severe asthma 49
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis 49
Effects of High-Flow Nasal Cannula on Right Heart Dysfunction in Patients with Acute-on-Chronic Respiratory Failure and Pulmonary Hypertension 48
Secretion management in patients with ineffective airway clearance with non-invasive mechanical ventilation use: Expert guidance for clinical practice 48
Airway hyperresponsiveness with chest strapping: A matter of heterogeneity or reduced lung volume? 48
Uneven use of noninvasive ventilation in acute respiratory failure in Europe 47
Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma 47
Benralizumab: from tissue distribution to eosinophilic cytotoxicity up to potential immunoregulation 46
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma 46
Long-Term High-Flow Nasal Therapy in Patients with Bronchiectasis of Different Severity: A Retrospective Cohort Study 45
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype 45
Novel Biological Therapies for Severe Asthma Endotypes 45
Incidence and diagnosis of HIT in patients undergoing thoracoabdominal aortic aneurysm (TAA) repair 44
The Link between Asthma and Bronchiectasis: State of the Art 44
Effect of Laboratory Testing Guidelines on the Utilization of Tests and Order Entries in a Surgical Intensive Care Unit 43
Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers 43
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 43
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 43
Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study 43
Clinical Recovery Should Be Considered as an Outcome Measure in Clinical Trials Including Patients With New-Onset Hypoxemia 42
Noninvasive continuous arterial pressure monitoring with Clearsight during awake carotid endarterectomy: A prospective observational study 42
Vitamin D and disease severity in bronchiectasis 42
Noninvasive Ventilation for Weaning and Post-Extubation Failure 42
High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study 42
Effectiveness of an educational intervention on different types of errors ­occurring during inhaler therapy use in COPD patients during a ­Pulmonary Rehabilitation Program 41
Totale 6.102
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202180 0 0 0 3 19 5 9 0 7 18 9 10
2021/2022126 12 20 0 2 17 0 20 2 14 2 3 34
2022/2023635 19 11 8 44 23 50 49 115 249 19 19 29
2023/2024690 24 78 40 59 29 125 16 69 7 34 135 74
2024/20253.402 69 454 223 109 616 373 131 83 229 304 307 504
2025/20263.290 593 1.129 1.511 57 0 0 0 0 0 0 0 0
Totale 8.346